Health and wellness group Ascendis Health said on Thursday it will sell three businesses within its Biosciences division to a consortium for R480m as part of a strategic review.
Ascendis will sell the Efekto, Marltons and Afrikelp businesses to a consortium comprising of RMB Ventures, Nedbank Private Equity and certain members of the management of the Ascendis Biosciences division, it said.
“Following our strategic business review last year the Biosciences division was considered as noncore to the group’s strategy and was identified for sale,” CEO Thomas Thomsen said.
“While these Biosciences businesses are performing well, they serve a different set of customers and require capabilities and skills that are not core to Ascendis Health.”
Ascendis shares jumped nearly 8% after the announcement and closed up 1.58% at R4.50.
Efekto manufactures and sells home and garden pesticides, fertiliser and plant food products and Afrikelp specialises in natural growth stimulants extracted from seaweed to improve the quality and quantity of agricultural crops. Marltons, established more than 80 years ago, manufactures and distributes pet care and pet products.
Thomsen said the cash proceeds from the sale will strengthen the group’s financial position in the short term and be used to reduce debt levels and fund working capital.
Ascendis, which also has operations in Cyprus, Hungary, Romania and Spain, said the remaining businesses in the Biosciences division, Avima and Klub M5, may be considered for divestment in the short to medium term.
The group has been divesting noncore assets as part of a strategic review aimed at improving cash generation, enhancing profitability and accelerating organic growth.
It announced the sale of its pharmaceutical manufacturing facility in Gauteng for R130m in December. This followed the sale of its South African sports nutrition business for R54m in September.
In January, the group received an unsolicited offer for its Cyprus-based generic pharmaceutical business Remedica.
Reuters
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.